Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020114519 - HETEROCYCLIC COMPOUND AS CDK-HDAC DUAL PATHWAY INHIBITOR

Publication Number WO/2020/114519
Publication Date 11.06.2020
International Application No. PCT/CN2019/124143
International Filing Date 09.12.2019
IPC
C07D 471/04 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
471Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
C07D 519/00 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
519Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/ or C07D455/257
A61K 31/519 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A61P 35/02 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
02specific for leukemia
CPC
A61K 31/519
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A61P 35/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
02specific for leukemia
C07D 471/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
471Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
C07D 519/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
519Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Applicants
  • 杭州英创医药科技有限公司 HANGZHOU INNOGATE PHARMA CO., LTD. [CN]/[CN]
Inventors
  • 张汉承 ZHANG, Hancheng
  • 叶向阳 YE, Xiangyang
  • 程鑫 CHENG, Xin
Agents
  • 上海一平知识产权代理有限公司 XU & PARTNERS, LLC.
Priority Data
201811497798.X07.12.2018CN
Publication Language Chinese (ZH)
Filing Language Chinese (ZH)
Designated States
Title
(EN) HETEROCYCLIC COMPOUND AS CDK-HDAC DUAL PATHWAY INHIBITOR
(FR) COMPOSÉ HÉTÉROCYCLIQUE À TITRE D'INHIBITEUR DE LA VOIE DOUBLE CDK-HDAC
(ZH) 作为CDK-HDAC双通路抑制剂的杂环化合物
Abstract
(EN)
Provided are a compound of formula (I) as shown below, and a pharmaceutically acceptable salt, a hydrate or a solvate thereof. Further provided are a pharmaceutical composition comprising the compound, a preparation method therefor and the use thereof in the treatment of diseases and conditions (including cancers).
(FR)
L'invention concerne un composé de formule (I) tel que présenté ci-dessous, et un sel pharmaceutiquement acceptable, un hydrate ou un solvate de celui-ci. L'invention concerne en outre une composition pharmaceutique comprenant le composé, son procédé de préparation et son utilisation dans le traitement de maladies et d'états pathologiques (y compris des cancers).
(ZH)
提供如下所示的式(I)的化合物及其药学上可接受的盐,水合物或溶剂合物。还提供了这些化合物的药物组合物,其制备方法,以及它们在治疗疾病和病症(包括癌症)中的用途。
Latest bibliographic data on file with the International Bureau